Glucose-insulin-potassium solution for acute myocardial infarction

Area of Science:

• Cardiology
• Internal Medicine
• Pharmacology

Background:

• Acute myocardial infarction (AMI) is a leading cause of mortality worldwide.
• Glucose-insulin-potassium (GIK) solution has been explored as a potential therapeutic agent in AMI management.
• Previous research on GIK in AMI has primarily focused on the prethrombolytic era.

Purpose of the Study:

• To critically review the existing literature on the role of glucose-insulin-potassium (GIK) solution in the management of acute myocardial infarction (AMI).
• To synthesize findings from studies investigating GIK's impact on mortality and morbidity in AMI patients.

Main Methods:

• A comprehensive literature search was conducted using the MEDLINE database from 1966 to October 2001.
• Search terms included 'glucose', 'insulin', 'potassium', and 'myocardial infarction'.
• The review included relevant English-language human studies and meta-analyses.

Main Results:

• Most studies evaluating GIK for AMI predate the widespread use of thrombolytic therapy.
• While many studies suggested a trend favoring GIK in reducing AMI mortality and morbidity, this was not universally observed.
• The Polish GIK study, a significant trial, was halted early due to increased mortality in the GIK treatment group.
• Variability in GIK dosage, treatment duration, and administration routes across studies complicates interpretation.

Conclusions:

• The available evidence on GIK for AMI is largely derived from studies conducted before modern reperfusion strategies.
• Concerns regarding increased mortality in at least one major trial warrant caution.
• Routine GIK infusion in AMI patients is not recommended until results from larger, contemporary studies become available.